Fmoc-L-Nva(3-Et)-OH

Chemischer Name: N-alpha-(9-Fluorenylmethyloxycarbonyl)-3-ethyl-L-norvaline // Synonyme: (S)-Fmoc-2-amino-3-ethyl-pentanoic acid, (S)-2-(((9H-fluoren-9-yl)methoxy)carbonylamino)-3-ethylpentanoic acid, Fmoc-Nva(3-Et)-OH

  • Art-Nr.:FAA5360
  • CAS Nr.:1310680-47-7
  • Formel:C22H25NO4
  • Molare Masse:367,44 g/mol

Startet von 300,00 €

Gruppiert Produkte - Artikel
Anzahl Verpackungsgröße Preis SKU
1 g
300,00 €
FAA5360.0001
5 g
1.200,00 €
FAA5360.0005
Sicherheitsdatenblätter
references

Discovery of Begacestat, a Notch-1-Sparing g-Secretase Inhibitor for the Treatment of Alzheimer’s Disease. S. C. Mayer, A. F. Kreft, B. Harrison, M. Abou-Gharbia, M. Antane, S. Aschmies, K. Atchison, M. Chlenov, D. C. Cole, T. Comery, G. Diamantidis, J. Ellingboe, K. Fan, R. Galante, C. Gonzales, D. M. Ho, M. E. Hoke, Y. Hu, D. Huryn, U. Jain, M. Jin, K. Kremer, D. Kubrak, M. Lin, P. Lu, R. Magolda, R. Martone, W. Moore, A. Oganesian, M. N. Pangalos, A. Porte, P. Reinhart, L. Resnick, D. R. Riddell, J. Sonnenberg-Reines, J. R. Stock, S.-C. Sun, E. Wagner, T. Wang, K. Woller, Z. Xu, M. M. Zaleska, J. Zeldis, M. Zhang, H. Zhou, and J. S. Jacobsen; J. Med. Chem. 2008; 51: 7348-7351. https://doi.org/10.1021/jm801252w.

Synthesis and structure-activity relationship of a novel series of heterocyclic sulfonamide g-secretase inhibitors. J. Pu, A. F. Kreft, S. H. Aschmies, K. P. Atchison, J. Berkowitz, T. J. Caggiano, M. Chlenov, G. Diamantidis, B. L. Harrison, Y. Hu, D. Huryn. J. S. Jacobsen, M. Jin, K. Lipinski. P. Lu. R. L. Martone, K. Morris, J. Sonnenberg-Reines, D. R. Riddell, J. Sabalski, S.-C. Sun, E. Wagner, Y. Wang, Z. Xu, H. Zhou, and L. Resnick; Bioorg. Med. Chem. 2009; 17: 4708-4717. https://doi.org/10.1016/j.bmc.2009.04.052.

Structure-activity relationships of tubulysin analogues. J. R. Courter, J. Z. Hamilton, N. R. Hendrick, M. Zaval, A. B. Waight, R. P. Lyon, P. D. Senter, S. C. Jeffrey, and P. J. Burke; Bioorg. Med. Chem. Lett. 2020; 30: 127241. https://doi.org/10.1016/j.bmcl.2020.127241.

Peptide Macrocycle Inhibitor of Coagulation Factor XII with Subnanomolar Affinity and High Target Selectivity. S. J. Middendorp, J. Wilbs, C. Quarroz, S. Calzavarini, A. Angelillo-Scherrer, and C. Heinis; J. Med. Chem. 2017; 60: 1151-1158. https://doi.org/10.1021/acs.jmedchem.6b01548.

Structure-activity relationship study of the tumour-targeting peptide A20FMDV2 via modification of Lys16, Leu13, and N- and/or C-terminal functionality. K.-y. Hung, P. W. R. Harris, A. Desai, J. F. Marshall, and M. A. Brimble; Eur. J. Med. Chem. 2017; 136: 154-164. https://doi.org/10.1016/j.ejmech.2017.05.008.

Lead Optimization Yields High Affinity Frizzled 7-Targeting Peptides That Modulate Clostridium difficile Toxin B Pathogenicity in Epithelial Cells. S. Hansen, A. H. Nile, S. C. Mehta, J. Fuhrmann, and R. N. Hannoush; J. Med. Chem. 2019; 62: 7739-7750. https://doi.org/10.1021/acs.jmedchem.9b00500.

Peptidomimetic ethyl propenoate covalent inhibitors of the enterovirus 71 3C protease: a P2-P4 study. M. J. Ang, Q. Y. Lau, F. M. Ng, S. W. Then, A. Poulsen, Y. K. Cheong, Z. X. Ngoh, Y. W. Tan, J. Peng, T. H. Keller, J. Hill, J. J. Chu, and C. S. B. Chia; J. Enzyme Inhib. Med. Chem. 2016; 3: 332-339. https://doi.org/10.3109/14756366.2015.1018245.

Enhanced antimalarial activity of plasmepsin V inhibitors by modification of the P2 position of PEXEL peptidomimetics. W. Nguyen, A. N. Hodder, R. Bestel de Lezongard, P. E. Czabotar, K. E. Jarman, M. T. O’Neill, J. K. Thompson, H. J. Sabroux, A. F. Cowman, J. A. Boddey, B. E. Sleebs; Eur. J. Med. Chem. 2018; 154: 182-198. https://doi.org/10.1016/j.ejmech.2018.05.022.


Bulk oder Großmengen-Bestellung?

Sie benötigen größere Mengen für Ihre Entwicklung oder Produktion?

Benötigen Sie weitere Informationen über dieses Produkt?

kontaktieren Sie uns

Schneller Kontakt

Bitte senden Sie mir mehr Informationen über

Produkte, die Sie auch interessieren könnten!